Summary of Conference Call on Investment Opportunities in the Beauty and Consumer Sector Industry Overview - The conference focused on the recent performance of the U.S. stock market, particularly the consumer sector's rebound and the rotation of funds from technology to consumer stocks, driven by positive market sentiment and policy support [1][2][3]. Key Insights - **Market Performance**: The U.S. stock market has shown strong performance, especially in consumer stocks, with a notable shift of funds from the technology sector to consumer sectors, indicating a recovery in consumer spending supported by favorable policies [3]. - **Investment Themes**: Three main investment themes were highlighted: 1. **Valuation of Industry Leaders**: Focus on industry leaders with reasonable valuations, such as Proya and Bethany, which have demonstrated strong market performance and product innovation [3][9]. 2. **High Growth Potential**: Companies with strong performance certainty and high growth potential, such as Shangmei Co., which is expected to expand its product categories and improve profitability through refined operations [4][10]. 3. **Premium Beauty and Domestic Brands**: Continued premiumization in high-end beauty products and domestic brands, with companies like Maogeping showing strong growth potential due to high customer loyalty and premium pricing strategies [5][11]. Company-Specific Analysis - **Proya**: Recognized for its ability to maintain steady growth through a big product strategy and multi-brand expansion, positioning itself as a leading domestic brand [9]. - **Bethany**: Highlighted for its quick response to market changes and commitment to quality, with expectations for significant growth in non-skincare products [10]. - **Shangmei Co.**: Noted for its impressive GMV data and rapid market response post-pandemic, with a focus on expanding its product lines and enhancing profitability through strong channel management [4]. - **HBN**: A new entrant in the market, HBN has established itself as a leading domestic skincare brand with a focus on effective skincare products. It reported a revenue of 1.5 billion in the first three quarters of 2025, with a 10% year-on-year growth [7][13]. - **Banmu Huatian**: Recently listed on the Hong Kong Stock Exchange, it reported a revenue of 1.9 billion in the first three quarters of 2025, marking a 77% increase year-on-year, with a strong online presence [6][12]. Emerging Trends - **Beauty and Health Products**: The discussion included the successful brand transformation of companies like Ruocheng, which has effectively shifted from operational to brand-focused strategies, and the market advantages of leading health brands like Feicui [5][10]. - **Research and Development**: HBN's commitment to R&D is underscored by its extensive patent portfolio and scientific publications, which enhance its market competitiveness and consumer trust [8][13]. Conclusion - The conference emphasized the importance of identifying investment opportunities in the consumer sector, particularly in beauty and health products, driven by market recovery and consumer demand. Investors are encouraged to engage with the research team for deeper insights into specific companies and market trends [2][9].

Core Viewpoint - The competition in anti-aging ingredients has evolved from mere concentration comparisons to a comprehensive battle focusing on targeting, safety, and mechanisms of action. The newly launched "human-like exosome HME" by Gu Yu has garnered attention for its unique cellular gene-level anti-aging mechanism, raising questions about its advantages over traditional ingredients like Bosen and A-Retinol [1][15]. Group 1: Mechanism Comparison - Human-like exosome HME represents a breakthrough in anti-aging ingredients, utilizing proprietary artificial exosome technology to simulate natural human exosomes, which are crucial for cellular communication [1]. - Bosen acts as a conservative anti-aging ingredient, stimulating glycosaminoglycan synthesis and enhancing the extracellular matrix in the dermis [3]. - A-Retinol, a derivative of Vitamin A, promotes skin renewal and collagen synthesis but is known for its strong irritation potential [5]. Group 2: Safety Comparison - Human-like exosome HME ensures safety by eliminating risk factors through high-precision engineering technology, complying with cosmetic ingredient regulations [6][7]. - Bosen may increase skin sensitivity and lead to adverse reactions such as redness and itching with prolonged use [8]. - A-Retinol poses significant safety risks, including skin irritation and phototoxicity, especially at higher concentrations [9]. Group 3: Efficacy and Innovation - Human-like exosome HME is backed by Gu Yu's comprehensive R&D capabilities, including advanced facilities and AI technology to optimize ingredient analysis and formulation [10]. - Bosen's efficacy is concentration-dependent, with noticeable effects typically requiring a minimum of 3% concentration [11][12]. - A-Retinol requires careful usage and gradual acclimatization due to its potential side effects, particularly in certain demographics [13][14]. Group 4: Choosing the Right Anti-Aging Ingredient - Human-like exosome HME is positioned as the future of anti-aging skincare, suitable for consumers seeking effective and safe solutions [15]. - Bosen is recommended for those with mild anti-aging needs, particularly for dry skin types [16]. - A-Retinol is ideal for consumers with resilient skin looking for rapid results, but caution is advised regarding its use [16].